Nimotop (Nimodipine)

Nimodipine blocks L‑type calcium channels on the smooth muscle of cerebral arteries. This reduces calcium entry, causing the vessels to relax and dilate, which increases cerebral perfusion and counteracts the narrowing (vasospasm) that can occur after a subarachnoid bleed.

The dose of Nimotop is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare professionals follow local guidelines and adjust the infusion rate as needed for each individual.

Safety data for nimodipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Nimotop, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimotop (nimodipine) is a calcium channel blocker specifically approved for vasospasm prevention after subarachnoid hemorrhage, whereas other agents such as magnesium sulfate or endothelin receptor antagonists are used off‑label or in research settings. Nimodipine’s vascular selectivity and extensive clinical experience make it a first‑line option in many protocols.

Nimotop should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Nimotop is supplied as an injectable solution for intravenous infusion. The infusion is typically administered over a set period under continuous monitoring of blood pressure and cardiac status, following the dosing instructions provided by the treating physician.

Serious risks include severe hypotension, myocardial infarction, allergic reactions such as anaphylaxis, and rare hepatic or hematologic abnormalities. Prompt recognition and medical management of these events are essential, and patients should be monitored closely during and after infusion.

Patients with known hypersensitivity to nimodipine or any component of the formulation should avoid Nimotop. Caution is also advised in individuals with uncontrolled severe hypotension, significant cardiac conduction disorders, or those taking interacting medications that could exacerbate blood pressure drops.